Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk ...

Researchers at the University of Iowa are part of a project designed to enhance treatment options for a common form of liver ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

According to Cancer Research UK, there are around 6,600 new liver cancer cases in the UK every year, and around 5,830 people ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

A new immune structure found in liver tumors could improve treatment for liver cancer patients. These structures are linked ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...

University of Iowa researchers have been awarded federal funding to help develop an effective drug combination to treat a ...